Staurosporines and structurally related indolocarbazoles as antitumor agents

Anticancer Agents from Natural Products

Volumn , Issue , 2005, Pages 499-518

  Prudhomme, Michelle ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL DEATH; CELL PROLIFERATION; ENZYMES; GENE EXPRESSION; PLANTS (BOTANY); POLYCYCLIC AROMATIC HYDROCARBONS; SIGNAL TRANSDUCTION;

ANTI-TUMOR AGENTS; BACTERIAL CULTURES; CELL-CYCLE ARREST; CYCLIN-DEPENDENT KINASE; FIVE-MEMBERED RINGS; KINASE INHIBITORS; SIGNAL TRANSDUCTION PATHWAYS; STREPTOMYCES SPECIES;

BACTERIA;

EID: 33646026356     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (119)

1. Prudhomme, M., Indolocarbazoles as anti-cancer agents, Curr. Pharm. Des., 3, 265, 1997.
2. Williams, D.E. et al., Holyrines A and B, possible intermediates in staurosporine biosynthesis produced in culture by a marine actinomycete obtained from the North Atlantic Ocean, Tetrahedron Lett., 40, 7171, 1999.
3. Schupp, P. et al., Staurosporine derivatives from the ascidian Eudistoma toealensis and predatory flatworm Pseudoceros sp., J. Nat. Prod., 62, 959, 1999.
4. Cantrell, C.H. et al., A new staurosporine analog from the prosobranch mollusk Coriocella nigra, Nat. Prod. Lett., 14, 39, 1999.
5. Hernandez, L.M.C. et al., 4-N-methyl-5-hydroxystaurosporine and 5-hydroxystaurosporine, new indolocarbazole alkaloïds from a marine Micromonospora sp. strain, J. Antibiot., 53, 895, 2000.
6. Schupp, P., Proksch, P. and Wray, V., Further new staurosporine derivatives from the ascidian Eudistoma toealensis and its predatory flatworm Pseudoceros sp., J. Nat. Prod., 65, 295, 2002.
7. Omura, S. et al., A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization, J. Antibiot., 30, 275, 1977.
8. Furusaki, A. et al., X-ray crystal structure of staurosporine: a new alkaloid from a Streptomyces strain, J. Chem. Soc. Chem. Commun., 800, 1978.
9. Steglich, W. et al., Indole pigments from the fruiting bodies of the slime mold Arcyria denudata, Angew. Chem. Int. Ed. Engl., 19, 459, 1980.
10. Tamaoki, T. et al., Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase, Biochem. Biophys. Res. Commun., 135, 397, 1986.
11. Kase, H., Iwahashi, K. and Matsuda, Y., K-252a, a potent inhibitor of protein kinase C from microbial origin, J. Antibiot., 39, 1059, 1986.
12. Cai, Y. et al., The staurosporine producing strain Streptomycetes longisporoflavus produces metabolites related to K-252a. Proposal for biosynthetic intermediates of K-252a, J. Antibiot., 49, 1060, 1996.
13. Yasuzawa, T. et al., The structures of the novel protein kinase C inhibitors K-252a, b, c, and d, J. Antibiot., 39, 1072, 1986.
14. Gray, N. et al., ATP-directed inhibitors of cyclin-dependent kinases, Curr. Med. Chem., 6, 859, 1999.
15. Hoehn, P., et al., 3-Demethoxy-3-hydroxystaurosporine, a novel staurosporine analog produced by a blocked mutant, J. Antibiot., 48, 300, 1995.
16. Rialet, V. and Meijer, L., A new screening test for antimitotic compounds using the universal M phasespecific protein kinase, p34cdc2/cyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates, Anticancer Res., 11, 1581, 1991.
17. Al-Obeidi, F.A. and Lam, K.S., Development of inhibitors for protein tyrosine kinases, Oncogene, 19, 5690, 2000.
18. Takahashi, I. et al., UCN-01 and UCN-02, new selective inhibitors of protein kinase C II. Purification, physico-chemical properties, structural determination and biological activities, J. Antibiot., 42, 571, 1989.
19. Jackson, J.R. et al., An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage, Cancer Res., 60, 566, 2000.
20. 2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase, J. Biol. Chem., 273, 33455, 1998.
21. Rodrigues Pereira, E. et al., Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties, J. Med. Chem., 39, 4471, 1996.
22. Kojiri, K. et al., A new antitumor substance, BE-13793C, produced by a Streptomycete, taxonomy, fermentation, isolation, structure determination and biological activity, J. Antibiot., 44, 723, 1991.
23. Facompré, M. et al., DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles, Mol. Pharmacol., 62, 1215, 2002.
24. Meggio, F. et al., Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2, Eur. J. Biochem., 234, 317, 1995.
25. Mahedevan, D.; Bearss, D.J. and Vankayalapati, H., Structure-based design of novel anti-cancer agents targeting aurora kinases, Curr. Med. Chem.-Anti-Cancer Agents, 3, 25, 2003.
26. Lawrie, A.M. et al., Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2, Nat. Struct. Biol., 4, 796, 1997.
27. Prade, L. et al., Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential, Structure, 5, 1627, 1997.
28. Lamers, M.B.A.C. et al., Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine, J. Mol. Biol., 285, 713, 1999.
29. Roy, K.K. and Sausville, E.A., Early development of cyclin dependent kinase modulators, Curr. Pharm. Des., 7, 1669, 2001.
30. Akiyama, T. et al., G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation, Jpn. J. Cancer Res., 90, 1364, 1999.
31. Sausville, E.A., Cyclin-dependent kinases: novel targets for cancer treatment, in Perry, M. Ed., 1999 Educational Book. American Society for Clinical Oncology, Alexandria, VA, 1999, 9.
32. Abe, S. et al., UCN-01 (7-hydroxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery, Jpn. J. Cancer Res., 92, 537, 2001.
33. Busby, E.C. et al., The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1, Cancer Res., 60, 2108, 2000.
34. Kohn, E.A. et al., Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation, J. Biol. Chem., 277, 26553, 2002.
35. Zhou, B.-B.S. and Elledge, S.J., The DNA damage response: putting checkpoints in perspective, Nature, 408, 433, 2000.
36. Cuddihy, A.R. and O’Connell, M.J., Cell-cycle responses to DNA damage in G2, Int. Rev. Cytol., 222, 99, 2003.
37. Nyberg, K.A. et al., Toward maintaining the genome: DNA damage and replication checkpoints, Annu. Rev. Genet., 36, 617, 2002.
38. Graves, P.R. et al., The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01, J. Biol. Chem., 275, 5600, 2000.
39. Tenzer, A. and Pruschy, M., Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators, Curr. Med. Chem.-Anti-Cancer Agents, 3, 35, 2003.
40. Yu, Q. et al., Inhibition of Chk2 activity and radiation-induced p53 elevation by the cell cycle checkpoint abrogator 7-hydroxystaurosporine (UCN-01), Proc. Am. Assoc. Cancer Res., 42, 800, 2001.
41. Zhao, B. et al., Structural basis for Chk1 inhibition by UCN-01, J. Biol. Chem., 277, 46609, 2002.
42. Sato, T.; Fujita, N. and Tsuruo, T., Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine), Oncogene, 21, 1727, 2002.
43. Roux, P.P. et al., K-252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK, J. Biol. Chem., 277, 49473, 2002.
44. Angeles, T.S., Kinetics of trkA tyrosine kinase activity and inhibition by K-252a., Arch. Biochem. Biophys., 349, 267, 1998.
45. Chin, L.S. et al., K-252a induces cell cycle arrest and apoptosis by inhibiting Cdc2 and Cdc25c, Cancer Invest., 17, 391, 1999.
46. Bush, J.A. et al., Production and biological activity of rebeccamycin, a novel antitumor agent, J. Antibiot., 40, 668, 1987.
47. Marminon, C. et al., Syntheses and antiproliferative activities of 7-azarebeccamycin analogs bearing one 7-azaindole moiety, J. Med. Chem., 46, 609, 2003.
48. Bailly, C. et al., DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin, Biochemistry, 36, 3917, 1997.
49. Kaneko, T. et al., Water soluble derivatives of rebeccamycin, J. Antibiot., 43, 125, 1990.
50. Prudhomme, M., Recent developments of rebeccamycin analogs as topoisomerase I inhibitors and antitumor agents, Curr. Med. Chem., 7, 1189, 2000.
51. Prudhomme, M., Rebeccamycin analogs as anti-cancer agents, Eur. J. Med. Chem., 38, 123, 2003.
52. Matson, J.A. et al., AT2433-A1, AT2433-A2, AT2433-B1, and AT2433-B2 novel antitumor antibiotic compounds produced by Actinomadura melliaura. Taxonomy, fermentation, isolation and biological properties, J. Antibiot., 42, 1547, 1989.
53. Carrasco, C. et al., DNA sequence recognition by the indolocarbazole antibiotic AT2433-A1 and its diastereoisomer, Nucleic Acids Res., 30, 1774, 2002.
54. Facompré, M. et al., DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles, Mol. Pharmacol., 62, 1215, 2002.
55. Knölker, H-J. and Reddy, K.R., Isolation and synthesis of biologically active carbazole alkaloïds, Chem. Rev., 102, 4303, 2002.
56. Sarstedt, B. and Winterfeldt, E., Reactions with indole derivatives XLVIII, a simple synthesis of staurosporin aglycon, Heterocycles, 20, 469, 1983.
57. Magnus, P.D., Exon, C. and Sear, N.L., Indole-2,3-quinodimethanes. Synthesis of indolocarbazoles for the synthesis of the fused dimeric indole alkaloïd staurosporinone, Tetrahedron, 39, 3725, 1983.
58. Joyce, R.P., Gainor, J.A. and Weinreb, S.M., Synthesis of the aromatic and monosaccharide moieties of staurosporine, J. Org. Chem., 52, 1177, 1987.
59. Brenner, M. et al., Synthesis of arcyriarubin B and related bisindolylmaleimides, Tetrahedron, 44, 2887, 1988.
60. Hughes, I., Nolan, W.P. and Raphael, R.A., Synthesis of the indolo[2,3-a]carbazole natural products staurosporinone and arcyriaflavin B, J. Chem. Soc. Perkin Trans. I, 2475, 1990.
61. Moody, C.J. et al., Synthesis of the staurosporin aglycon, J. Org. Chem., 57, 2105, 1992.
62. Mc Combie, S.W. et al., Indolocarbazoles. 1. Total synthesis and protein kinase inhibiting characteristics of compounds related to K-252c, Bioorg. Med. Chem. Lett., 3, 1537, 1993.
63. Link, J.T., Gallant, M. and Danishefsky, S.J., The first synthesis of a fully functionalized core structure of staurosporine: sequential indolyl glycosidation by endo and exo glycals, J. Am. Chem. Soc., 115, 3782, 1993.
64. Link, J.T., Raghavan, S. and Danishefsky, S.J., First total synthesis of staurosporine and ent-staurosporine, J. Am. Chem. Soc., 117, 552, 1995.
65. Link, J.T. et al., Staurosporine and ent-staurosporine: the first total syntheses, prospects for a regioselective approach, and activity profiles, J. Am. Chem. Soc., 118, 2825, 1996.
66. Wood, J.L. et al., Design and Implementation of an efficient synthetic approach to furanosylated indolocarbazoles: total synthesis of (+)-and (-)-K252a, J. Am. Chem. Soc., 119, 9641, 1997.
67. Wood, J.L. et al., Design and Implementation of an efficient synthetic approach to pyranosylated indolocarbazoles: total synthesis of (+)-RK286c, (+)-MLR-52, (+)-staurosporine and (-)-TAN-1030a, J. Am. Chem. Soc., 119, 9652, 1997.
68. Kobayashi, Y.; Fujimoto, T. and Fukuyama, T., Stereocontrolled total synthesis of (+)-K252a, J. Am. Chem. Soc., 121, 6501, 1999.
69. Kaneko, T. et al., Two synthetic approaches to rebeccamycin, Tetrahedron Lett., 26, 4015, 1985.
70. Gallant, M., Link, J.T. and Danishefsky, S.J., A stereoselective synthesis of indole-b -N-glycosides: an application to the synthesis of rebeccamycin, J. Org. Chem., 58, 343, 1993.
71. Faul, M.M., Winneroski, L.L. and Krumrich, C.A., Synthesis of rebeccamycin and 11-dechlororebeccamycin, J. Org. Chem., 64, 2465, 1999.
72. Bonjouklian, R. et al., Tjipanazoles, new antifungal agents from the blue-green alga Tolypothrix tjipanasensis, Tetrahedron, 37, 7739, 1991.
73. Gilbert, E.J. and Van Vranken, D.L., Control of dissymmetry in the synthesis of (+)-tjipanazole F2, J. Am. Chem. Soc., 118, 5500, 1996.
74. Gilbert, E.J., Ziller, J.W. and Van Vranken, D.L., Cyclizations of unsymmetrical bis-1,2-(3-indolyl)ethanes: synthesis of (-)-tjipanazole F1, Tetrahedron, 53, 16553, 1997.
75. Chisholm, J.D. and Van Vranken, D.L., Regiocontrolled synthesis of the antitumor antibiotic AT2433-A1, J. Org. Chem., 65, 7541, 2000.
76. Meyer, T. et al., A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity, Int. J. Cancer, 43, 851,1989.
77. Hoehn, P. et al, 3-Demethoxy-3-hydroxystaurosporine, a novel staurosporine analog produced by a blocked mutant, J. Antibiot., 48, 300, 1995.
78. Akinaga, S., Diverse effects of indolocarbazole compounds on the cell cycle progression of rastransformed rat fibroblast cells, J. Antibiot., 46, 1767, 1993.
79. Yamashita, Y. et al., Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives, Biochemistry, 31, 12069, 1992.
80. Jackson J.R. et al., An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage, Cancer Res., 60, 566, 2000.
81. Fuse, E. et al., Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-acid glycoprotein, Cancer Res., 58, 3248, 1998.
82. Sausville, E. et al., Phase I trial of 72-hour continuous infusion of UCN-01 in patients with refractory neoplasms, J. Clin. Oncol., 19, 2319, 2001.
83. Eastman, A. et al., A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01, Molecular Cancer Therapeutics, 1, 1067, 2002.
84. Traxler, P. et al., Tyrosine kinase inhibitors: from rational design to clinical trials, Med. Res. Rev., 21, 499, 2001.
85. Laird, A.D. and Cherrington, J.M., Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents, Expert Opin. Investig. Drugs, 12, 51, 2003.
86. Gingrich, D.E. and Hudkins, R.L., Synthesis and kinase inhibitory activity of 3-(S)-epi-K-252a, Bioorg. Med. Chem. Lett., 12, 2829, 2002.
87. Maroney, A.C. et al., CEP1347 (KT7515), a semi-synthetic inhibitor of the mixed lineage kinase family, J. Biol. Chem., 276, 25302, 2001.
88. Roux, P.P. et al., K252a and CP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK, J. Biol. Chem., 277, 49473, 2002.
89. Nheu, T.V. et al., The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants, Cancer J., 8, 238, 2002.
90. Kojiri, K. et al., A new antitumor substance, BE-13793C, produced by a Streptomycete. Taxonomy, fermentation, isolation, structure determination and biological activity, J. Antibiot., 44, 723, 1991.
91. Tanaka, S. et al., A new indolopyrrolocarbazole antitumor substance, ED-110, a derivative of BE-13793C, J. Antibiot., 45, 1797, 1992.
92. Kanzawa, F. et al., Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB, Cancer Res., 55, 2806, 1995.
93. Yoshinari, T. et al., Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I, Cancer Res., 59, 4271, 1999.
94. Ohkubo, M. et al., Synthesis and biological activities of NB-506 analogs modified at the glucose group, Bioorg. Med. Chem. Lett., 10, 419, 2000.
95. Yoshinari, T. et al., Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110, Cancer Res., 53, 490, 1993.
96. Bailly, C. et al., Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities, J. Med. Chem., 42, 2927, 1999.
97. Bailly, C. et al., Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents, Cancer Res., 59, 2853, 1999.
98. Facompré, M. et al., Apoptotic response of HL-60 human leukemia cells to the antitumor drug NB-506, a glycosylated indolocarbazole inhibitor of topoisomerase I, Biochem. Pharmacol., 61, 299, 2001.
99. Takenaga, N. et al., In vitro metabolism of a new anticancer agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]-5,7(6H)-dione (NB-506), in mice, rats, dogs and humans, Drug Metabol. Disposition, 27, 213, 1999.
100. Takenaga, N. et al., In vivo metabolism of a new anticancer agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]-5,7(6H)-dione (NB-506), in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites, Drug Metabol. Disposition, 27, 205, 1999.
101. Goossens, J.-F. et al., Plasma stability of two glycosyl indolocarbazole antitumor agents, Biochem. Pharmacol., 65, 25, 2003.
102. Long, B.H. et al, Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles, Curr. Med. Chem.-Anti-Cancer Agents, 2, 255, 2002.
103. Anizon, F. et al., Rebeccamycin analogs bearing amine substituents or other groups on the sugar moiety, Bioorg. Med. Chem., 11, 3709, 2003.
104. Anizon, F. et al., Synthesis, biochemical and biological evaluation of staurosporine analogs from the microbial metabolite rebeccamycin, Bioorg. Med. Chem., 6, 1597, 1998.
105. Marminon, C. et al., Syntheses and antiproliferative activities of new rebeccamycin derivatives with the sugar unit linked to both indole nitrogen, J. Med. Chem., 45, 1330, 2002.
106. Facompré, M. et al., DNA targeting of two new antitumor rebeccamycin derivatives, Eur. J. Med. Chem., 37, 925, 2002.
107. Moreau, P. et al., Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives, Bioorg. Med. Chem., 11, 4871, 2003.
108. Marminon, C. et al., Syntheses and antiproliferative activities of 7-azarebeccamycin analogs bearing one 7-azaindole moiety, J. Med. Chem., 46, 609, 2003.
109. Marminon, C. et al., Syntheses and antiproliferative activities of rebeccamycin analogs bearing two 7-azaindole moieties, Bioorg. Med. Chem., 11, 679, 2003.
110. Dancey, J. and Sausville, E.A., Issues and progress with protein kinase inhibitors for cancer treatment, Nat. Rev. Drug Discovery, 2, 297, 2003.
111. Walder, S., Perspectives for cancer therapies with CDK2 inhibitors, Drug Resistance Update, 4, 347, 2001.
112. Senderowicz, A.M., Preclinical and clinical development of CDK inhibitors, Proceedings 1st International Symposium on Signal Transduction Modulators in Cancer Therapy, Amsterdam, 2002, p 41.
113. Sausville, E.A. et al., Signal transduction-directed cancer treatments, Ann. Rev. Pharmacol. Toxicol., 43, 199, 2003.
114. Ganeshaguru, V.A. et al., A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C, Hematol. J., 3, 131, 2002.
115. Merchant, J. et al., Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analog, given in both single-dose and multiple dose-formats, Clin. Cancer Res., 8, 2193, 2002.
116. Tolcher, A.W. et al., Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties, J. Clin. Oncol., 19, 2937, 2001.
117. Dowlati, A. et al., Phase I and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days, J. Clin. Oncol., 19, 2309, 2001.
118. Goel, S. et al., A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer, Invest. New Drugs, 21, 103, 2003.
119. Hussain, M. et al., A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer, Invest. New Drugs, 21, 465, 2003.